Study Detail

« Back to Search Results Notify Me When Search is Updated

MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

ClinicalTrials.gov Identifier: NCT06008756 (view full study on clinicaltrials.gov)
Condition:  Arteriosclerosis, Hypercholesterolaemia
Status:  Recruiting


Official Title: Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of MK-0616, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of MK-0616 compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial revascularization.

Study Type:
Interventional
Study Phase:
Phase 3
Estimated Enrollment:
14550
Study Start Date:
October 2023
Estimated Study Completion Date:
November 2029
Estimated Primary Completion Date:
November 2029
Ages Eligible for Study:
18 years and older
Genders Eligible for Study:
All
Accepts Healthy Volunteers:
No


CRITERIA

Inclusion Criteria:

  • Meets one of the following:
    1. Age ≥18 years with a history of a major atherosclerotic cardiovascular disease (ASCVD) event defined as at least 1 of the following: ≥30 days post MI (presumed Type 1 due to plaque rupture or erosion); ≥30 days post ischemic stroke (presumed due to atherosclerosis); or ≥30 days post successful peripheral (carotid or lower extremity) arterial revascularization (surgical or endovascular) or major (ankle or above) amputation due to atherosclerosis; or
    2. High risk for first major ASCVD event defined as at least 1 of the following: Age ≥50 years with evidence of coronary artery disease; Age ≥50 years with evidence of atherosclerotic cerebrovascular disease; Age ≥50 years with evidence of peripheral arterial disease; or Age ≥60 years with diabetes mellitus and at least one of the following: microvascular disease or urine albumin-creatinine ratio ≥30 mg/mmol within 6 months before Visit 1, daily insulin use, or diabetes for ≥10 years
  • Has fasted lipid values (evaluated by the Central Laboratory) at Visit 1 (Screening) as follows:
    1. History of major ASCVD Event: LDL-C ≥70 mg/dL (1.81 mmol/L) OR non-HDL-C ≥100 mg/dL (2.59 mmol/L)
    2. High risk for first major ASCVD Event: LDL-C ≥90 mg/dL (2.33 mmol/L) OR non-HDL-C ≥120 mg/dL (3.11 mmol/L)
  • Is treated with moderate- or high-intensity statin (± nonstatin lipid-lowering therapy [LLT]) at Visit 1
  • Is on a stable dose of all background LLTs (including statin and nonstatin agents) for at least 30 days before Visit 1 (Screening) with no medication or dose changes planned during the participation in the study

Exclusion Criteria:

  • Has a history of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria, compound heterozygous FH, or double heterozygous FH
  • Has New York Heart Association Class IV heart failure, last known Left Ventricular Ejection Fraction ≤25% by any imaging method, or had a Heart Failure hospitalization within 3 months before Visit 1 (Screening)
  • Has recurrent ventricular tachycardia within 3 months prior to randomization
  • Has a planned arterial revascularization procedure
  • Is undergoing or previously underwent an LDL-C apheresis program within 3 months before Visit 1 (Screening) or plans to initiate an LDL-C apheresis program
  • Was previously treated/is being treated with certain other cholesterol lowering medications, including protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors without adequate washout.
  • Has a fasting triglyceride value ≥400 mg/dL (≥4.52 mmol/L) at Visit 1 (Screening)
  • Has history of severe renal insufficiency defined as estimated glomerular filtration rate <30 mL/min/1.73 m2 at Visit 1 (Screening) or has end-stage renal disease on dialysis.

United States     Toll Free Number     1-800-770-4674   

  • Alexander City, Alabama, 35010
  • Birmingham, Alabama, 35205
  • Birmingham, Alabama, 35209
  • Daphne, Alabama, 36526
  • Foley, Alabama, 36535
  • Phoenix, Arizona, 85020
  • Beverly Hills, California, 90211
  • La Jolla, California, 92037
  • Lancaster, California, 93534
  • Los Angeles, California, 90057
  • San Mateo, California, 94403
  • Tarzana, California, 91356-3551
  • Toluca Lake, California, 91602
  • Torrance, California, 90502
  • Aurora, Colorado, 80045
  • Littleton, Colorado, 80120
  • Stamford, Connecticut, 06905
  • Waterbury, Connecticut, 06708
  • Washington, District of Columbia, 20009
  • Boca Raton, Florida, 33434
  • Cutler Bay, Florida, 33189
  • Fort Myers, Florida, 33912
  • Jacksonville, Florida, 32205
  • Jacksonville, Florida, 32209
  • Jacksonville, Florida, 32216
  • Jacksonville, Florida, 32216
  • Lake City, Florida, 32055
  • Miami, Florida, 33125
  • MIAMI LAKES, Florida, 33014
  • Miramar, Florida, 33027
  • Ocala, Florida, 34471
  • Port Orange, Florida, 32127
  • St. Augustine, Florida, 32086
  • WINTER PARK, Florida, 32789
  • Macon, Georgia, 31210
  • Woodstock, Georgia, 30189
  • Chicago, Illinois, 60602
  • Chicago, Illinois, 60640
  • Flossmoor, Illinois, 60422
  • Gurnee, Illinois, 60031
  • Evansville, Indiana, 47714
  • Fort Wayne, Indiana, 46845
  • Indianapolis, Indiana, 46237
  • Kansas City, Kansas, 66160
  • Topeka, Kansas, 66606
  • Wichita, Kansas, 67207
  • Lexington, Kentucky, 40509
  • Louisville, Kentucky, 40213
  • Crowley, Louisiana, 70526
  • Monroe, Louisiana, 71201
  • Bangor, Maine, 04401
  • Boston, Massachusetts, 02131
  • Dearborn, Michigan, 48126
  • Grand Rapids, Michigan, 49546
  • Troy, Michigan, 48098
  • Maplewood, Minnesota, 55109
  • Gulfport, Mississippi, 39503
  • Hazelwood, Missouri, 63042
  • Kansas City, Missouri, 64114
  • Elkhorn, Nebraska, 68022
  • Lincoln, Nebraska, 68506
  • Las Vegas, Nevada, 89109
  • LAS VEGAS, Nevada, 89121-4350
  • Bridgewater, New Jersey, 08807
  • Washington Township, New Jersey, 08080
  • Albuquerque, New Mexico, 87106
  • Binghamton, New York, 13905
  • Manlius, New York, 13104
  • New Hyde Park, New York, 11042
  • New Windsor, New York, 12553
  • Rochester, New York, 14609
  • ROSEDALE, New York, 11422
  • Winston-Salem, North Carolina, 27157
  • FARGO, North Dakota, 58104
  • Cincinnati, Ohio, 45246
  • Dayton, Ohio, 45414
  • Oklahoma City, Oklahoma, 73135
  • Camp Hill, Pennsylvania, 17011
  • Yardley, Pennsylvania, 19067
  • Anderson, South Carolina, 29621
  • North Charleston, South Carolina, 29405
  • Rapid City, South Dakota, 57701
  • Bristol, Tennessee, 37620
  • Kingsport, Tennessee, 37660
  • Knoxville, Tennessee, 37909
  • Houston, Texas, 77054
  • Odessa, Texas, 79761
  • Pearland, Texas, 77584
  • San Antonio, Texas, 78233
  • San Antonio, Texas, 78258
  • Sugar Land, Texas, 77479
  • Tomball, Texas, 77375
  • Salt Lake City, Utah, 84106
  • Salt Lake City, Utah, 84124
  • West Jordan, Utah, 84088
  • Burke, Virginia, 22015
  • Charlottesville, Virginia, 22911
  • Falls Church, Virginia, 22042
  • Manassas, Virginia, 20109
  • Manassas, Virginia, 20110
  • Newport News, Virginia, 23606
  • Norfolk, Virginia, 23502
  • Suffolk, Virginia, 23435

Canada     Study Coordinator     418-545-1252   

No Study Results Posted



Find a Study in US or Canada

Advanced Search    Search All Studies

RELATED INFORMATION



Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site